The long half-lives of the circulating proteins might be one reason why circulating proteins mirrored the therapy response less sensitively compared to, i.e., PIK3CA mutations in cfDNA of BC patients [90] and the tumor fraction in the cfDNA [89]. The gene discussed is PIK3CA; the disease is breast cancer.